原发性宫颈弥漫性大 B 细胞淋巴瘤：罕见实体的治疗结果及文献回顾。
Primary diffuse large B cell lymphoma of Uterine Cervix: Treatment outcomes of a rare entity with literature review.
机构信息
Adult Hematolymphoid Disease Management Group, Tata Memorial Centre, Homi Bhaba National Institute, Mumbai, India.
出版信息
Cancer Rep (Hoboken). 2020 Oct;3(5):e1264. doi: 10.1002/cnr2.1264. Epub 2020 Aug 6.
BACKGROUND
Primary lymphomas involving the female genital tract are rare, and those arising from cervix are extremely uncommon. They are often misdiagnosed because of their rarity.
METHODS AND CASES
The treatment and clinical outcomes of the four cases treated at our institution were compared with the previously published studies. Written informed consent was taken. We highlight four cases of primary diffuse large B-cell lymphoma of cervix treated at our institution with immunochemotherapy and radiotherapy. The mean age was 50 years (range, 39-62 years). Three patients had stage I disease while one had stage II disease. All the patients were in complete remission following treatment with immunochemotherapy and radiation therapy. The average disease free survival was 20 months (range, 8-43 months). None of the patients had any local or systemic relapse.
CONCLUSION
These cases highlight the physicians to be aware of this entity as their management, natural history and prognosis is completely different from squamous carcinomas of the cervix. Surgery should not be attempted in these patients. Immunochemotherapy and radiotherapy results in favorable clinical outcomes.
背景
原发性女性生殖道淋巴瘤少见，起源于宫颈的更为罕见。由于其罕见性，常被误诊。
方法和病例
将我院收治的 4 例患者的治疗和临床结局与既往文献报道的病例进行比较，并取得了书面知情同意。我们强调了在我院接受免疫化疗和放疗治疗的 4 例原发性宫颈弥漫性大 B 细胞淋巴瘤病例。平均年龄 50 岁（范围 39-62 岁）。3 例患者为Ⅰ期疾病，1 例为Ⅱ期疾病。所有患者经免疫化疗和放疗后均达到完全缓解。平均无疾病进展生存期为 20 个月（范围 8-43 个月）。所有患者均无局部或全身复发。
结论
这些病例提醒医生注意这一实体，因为它们的治疗、自然史和预后与宫颈鳞癌完全不同。这些患者不应进行手术。免疫化疗和放疗可获得良好的临床结局。
Zotero 插件